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Perfluoroalkylated and polyfluoroalkylated substances (PFASs) represent a 
large class of man-made chemicals. These substances have emerged as environmental 
contaminants due to their extraordinary resistance to degradation, potential for 
bioaccumulation, toxicity and a global presence in humans, wildlife and the 
environment. In the Swedish population 17 PFASs have so far been analyzed in blood. 
In animal studies, PFASs cause liver toxicity and reproductive/developmental toxicity 
as well as a range of other toxic effects. Detailed data on the tissue distribution of 
PFASs, which could contribute to better understanding of their toxicity, are limited. 
Also, health risk assessment information has been lacking for all PFASs except the 
most studied, perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA).  
The aims of this thesis were to 1) generate detailed tissue distribution data on 
PFOS in perinatal and adult mice and on its replacement chemical perfluorobutane 
sulfonate (PFBS) in adult mice; and 2) and assess potential risks to human health 
associated with exposure to the 17 PFASs analyzed in the general Swedish population 
and occupationally exposed ski waxers, for all PFASs individually and in combination.  
The results of the experiments showed that following exposure of pregnant 
dams PFOS was readily transferred to mouse fetuses resulting in tissue levels similar to 
or higher than maternal blood levels. PFOS was markedly distributed to the perinatal 
and maternal lungs; showing the highest levels of the tissues analyzed in fetuses/pups 
on gestational day 20 and postnatal day 1. This finding may help to explain the 
respiratory distress seen in neonatal and adult rodents following exposure to PFOS. 
Further, in adult male mice after short-term dietary exposure to one environmentally 
relevant low dose and one experimentally relevant high dose, PFOS was recovered in 
all 19 examined tissues, with similar tissue distribution profiles at both doses, though 
with a higher tissue:blood ratio at the higher dose. The highest concentrations of PFOS 
were found in liver, lungs, blood, kidneys and whole bone and the major body 
compartments were liver, bone, blood, skin and muscle. Blood hemoglobin levels were 
markedly increased at the high dose which could be connected to the localization of 
PFOS in bone marrow. In a similar experiment PFBS was recovered in all 20 examined 
tissues in adult male mice after short-term dietary exposure to the same molar 
concentration as the high dose of PFOS. The distribution and compartment profiles 
were similar to those of PFOS with the exception of a remarkably high concentration in 
cartilage. Also, PFBS displayed significantly lower tissue concentrations and tissue: 
blood ratios than PFOS and a less marked erythropoietic effect.  
The risk assessment of PFASs showed that hepatotoxicity and reproductive/ 
developmental toxicity may be of concern for high local exposure and occupational 
exposure but indicated no risk for the general population. Concern for the less studied 
endpoints immunotoxicity and altered mammary gland development was identified for 
the general population and the occupationally exposed. A need of additional 
toxicological data for all investigated toxicological endpoints was recognized.  
Altogether, the work included in this thesis has generated experimental data that 
can be used to improve risk assessment of PFASs. It has also assessed the risks 
associated with current exposures to PFASs in Sweden and identified data needs.  
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1.1 CHEMICALS AND ENVIRONMENTAL CONTAMINANTS 
Our society is characterized by a broad use of chemicals and humans are exposed 
directly or indirectly to a variety of chemical substances on a daily basis. As a result of 
their intrinsic properties some chemicals end up in the environment and in human 
populations, even in remote areas where they have never been produced or used. An 
increasing number of experimental and epidemiological studies indicate that exposure 
to low doses of certain chemicals may give rise to a wide range of adverse health 
effects, including neurotoxicity, metabolic diseases, immune deficiency, impaired 
reproduction and cancer (reviewed in Hotchkiss et al. 2008; reviewed in Wigle et al. 
2008). Fetuses are particularly sensitive due to critical developmental periods and the 
effects may manisfest first much later in life. The World Health Organization (WHO) 
estimates that more than 25% of the global disease burden is linked to environmental 
factors, including exposure to hazardous chemicals (IPCS/WHO 2010). In the view of a 
ten-fold worldwide increase in production and use of chemicals during the last 40 
years, which is expected to increase even further (IPCS/WHO 2010), it is of great 
importance that we have sufficient knowledge about chemicals and how to use them in 
ways that are safe for human health and the environment. 
 
A number of individual chemicals and groups of chemicals have during the past 50 
years been classified as environmental contaminants or persistent organic pollutants 
(POPs) based on their persistent, bioaccumulative and toxic properties. In particular, 
many of these contaminants are halogenated hydrocarbons containing chlorine, 
bromine or fluorine. In the 1960s and 1970s, chlorinated compounds such as the 
insecticide DDT, the polychlorinated biphenyls (PCBs) used as electric insulators, and 
dioxins which are formed unintentionally in various industrial and combustion 
processes, were discovered and recognized as POPs (Naturvårdsverket 1998; UNEP 
2013). In the 1970s and 1980s, brominated compounds, used as flame retardants in 
potentially flammable materials, were discovered in humans and wildlife far from local 
sources and identified as environmental contaminants (Law et al. 2003; Rahman et al. 
2001; Sjödin et al. 2003). In the late 1990s and the early 2000s, the perfluorinated and 
polyfluorinated substances (PFASs) were found in wildlife and human blood, similarly 
as the chlorinated and brominated compounds.  
 
1.2 PER- AND POLYFLUOROALKYLATED SUBSTANCES (PFASS) 
Perfluoroalkylated and polyfluoroalkylated substances (PFASs) belong to a family of 
more than 800 man-made, highly fluorinated, organic chemicals that have been used 
since the 1950s as components of and precursors for surfactants and surface protectors 
in industrial and consumer applications (3M 1999; Kissa 2001; OECD 2007).  
 
In 2001, it was reported that perfluorooctane sulfonate (PFOS) was present globally in 
a wide range of wildlife species (Giesy and Kannan 2001; Giesy et al. 2001; Kannan et 
al. 2001). Similarly in 2001, the presence of PFOS, perfluorooctanoic acid (PFOA) and 
other PFASs in the blood of the general population in the Unites States was reported 
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(Hansen et al. 2001). The authors also suggested that PFASs were responsible for a 
considerable fraction of the organic fluorine that has been detected in serum of non-
occupationally exposed human populations since the 1960s, but where compound-
specific analytical methods were not available at that time. Since 2001, a large number 
of biomonitoring and toxicological studies on PFASs have been published and PFASs 
have been recognized as highly persistent environmental contaminants and generated 
concern due to their global presence in humans, wildlife and the environment. 
 
1.2.1 Physicochemical properties  
PFASs are characterized by their fully (per-) or partly (poly-) fluorinated carbon 
chains, typically four to fifteen carbons long and with a functional group at one of 
their tails (Figure 1). Due to the strength of the carbon-fluorine bond, one of the 
strongest chemical bonds known, PFASs are extremely resistant towards thermal, 
chemical and biological degradation (Järnberg et al. 2006; Kissa 2001). In addition, 
the fluorinated carbon chain is both oil-and water repellent (Kissa 2001), making 
PFASs useful in many industrial and consumer applications. However, their 
resistance to degradation also makes them persistent in the environment. 
Perfluorinated sulfonates and carboxylates are considered stable end-stage products 
that will not degrade under any normal environmental circumstances (Järnberg et al. 
2006). They can, however, be generated from the degradation of precursor molecules, 
e.g. the polyfluorinated 8:2 fluorotelomer alcohol (8:2 FTOH) that can generate 
PFOA with the same “backbone” structure (reviewed in Frömel and Knepper. 2010, 
Figure 1). Perfluorinated sulfonates and carboxylates are strong acids and mainly 
present in their non-volatile acid forms in the environment and in biota. 
Fluorotelomers, on the other hand, are volatile and can be transported in the 
atmosphere (Houde et al. 2006).  
 
 
1.2.2 Nomenclature  
PFASs are named according to the number of carbons on the alkyl chain and their 
respective functional group, e.g. the four carbon chain with a sulfonate group is 
named perfluorobutane sulfonate (PFBS). For many years there has been an 
inconsistent terminology used for PFASs, with different and sometimes overlapping 
abbreviations. Recently, however, Buck et al. (2011) proposed a terminology and 
classification scheme for PFASs which is also used herein:  
Figure 1. Schematic chemical structures of perfluorinated sulfonates (1), carboxylates (2) and fluorotelomer alcohols 
(3), including perfluorooctane sulfonate (PFOS), perfluorooctanoate (PFOA) and 6:2 FTSA. 
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 PFASs = Perfluoroalkylated and polyfluoroalkylated substances (singular PFAS). 
 PFAA = Perfluoroalkylated acid. 
 PFSA = Perfluoroalkylated sulfonic acid. 
 PFCA = Perfluoroalkylated carboxylic acid. 
 Long-chain PFASs = PFSAs with ≥ 6 carbons and PFCAs with ≥ 8 carbons. 
 Homologues = Different PFASs sharing the same functional group. 
 
Further, the term “congener” used herein represents individual PFASs.  
 
1.2.3 Uses of PFASs 
PFASs have been widely used as components of and precursors for surfactants and 
surface protectors in industrial applications and consumer products. Examples include 
impregnating agents for clothing and textiles, coatings for paper and packaging, 
waxes (including ski waxes) and cleaning agents, insecticides, fire-fighting foams, 
hydraulic fluids in airplanes and process chemicals in the manufacture of 




 (3M 1999; KemI 2009; Kissa 2001). 
 
1.2.4 Sources to the environment 
PFASs can be released to the environment during their entire life-cycle, at production 
and use, from products containing PFASs, and after their use as leakage from e.g. 
waste disposals and landfills. Aqueous film-forming foams (AFFFs) used for fire-
fighting have been pointed out as a significant source of PFOS and other PFASs, as 
demonstrated by elevated levels around fire-fighting training areas (Weiss et al. 2012) 
and airports where AFFFs have been used (Moody et al. 2003; Nunes et al. 2011). 
Also, atmospheric degradation of volatile precursor molecules, e.g. fluorotelomers 
forming PFCAs is likely to occur (Ellis et al. 2004). There is and has not been any 
production of PFASs in Sweden (KemI 2006) and the PFASs detected in the Swedish 
environment is likely a result of release from industrial and consumer use of PFASs 
and PFASs-containing products, leakage from waste disposals, landfills and sewage 
treatment plants as well as from atmospheric import.  
 
1.2.5 Biological behavior 
In the environment, PFASs are associated mostly to aquatic ecosystems. This is likely 
due to their solubility in water (reviewed in Rayne and Forest. 2009) and their ability 
to bioaccumulate in fish, with the bioconcentration factor (BCF) being proportional to 
carbon chain length, at least up to a chain length of 11 carbons (Martin et al. 2003). 
PFASs can also biomagnify in food chains, as demonstrated by the highest levels 
being found in top predators such as the polar bear, mink, otter and seal (Giesy and 
Kannan 2001; Kannan et al. 2002, 2005; Kelly et al. 2009). In contrast to “classic” 
persistent organic contaminants, e.g. chlorinated and brominated compounds, PFASs 
does not distribute to and store up in fatty tissues in living organisms, but bind to 
proteins such as albumin in liver, plasma and eggs, and fatty acid binding proteins in 
cells due to their structural similarity to endogenous fatty acids (Kannan et al. 2005; 




1.2.6 Human exposure  
1.2.6.1 Sources 
Food, in particular fish and seafood, is proposed to be the main source of human 
exposure for several PFASs and may account for as much as 99% and 84% of the 
total PFOS and PFOA intake, respectively (Haug et al. 2010). However, dust may 
also represent a major source on an individual basis (Haug et al. 2011). Fetuses are 
exposed via placental transfer during pregnancy (Kim et al. 2011) and breast milk is 
the main source of PFASs for infants (Haug et al. 2011), through which their intake 
may equal the dietary intake in adults (Thomsen et al. 2010). The highest exposures 
occur in occupational settings, most likely through inhalation of PFASs-containing 
aerosols and dust (reviewed in ATDSR 2009; Vestergren and Cousins 2009). The 
highest PFASs levels have been detected in individuals in PFASs production facilities 
(reviewed in Lau et al. 2007). In Sweden, professional ski waxers have shown the 
highest serum concentrations of PFASs (Nilsson et al. 2010). 
 
1.2.6.2 Measures of human exposure to PFASs 
Serum concentrations of PFASs are commonly used as measure of human exposure. 
Blood/serum is a suitable matrix to analyze based on the relatively long half-lives of 
many PFASs in humans, spanning from months to years (reviewed in Lau 2012a). One 
advantage of using blood/serum concentrations is also that these represent an integrated 
measure of exposure for PFSAs and PFCAs irrespective of the source, e.g. precursor 
molecules that can be metabolized to e.g. PFOS and PFOA. Another advantage of 
using serum concentrations is that it enables easy comparisons to internal dose levels in 
animal studies and facilitates kinetic extrapolations from animals to humans.  
 
1.2.6.3 Human exposure levels 
In human populations of western countries such as Sweden, Germany and the United 
States, PFAS congeners are commonly found at low ng/ml serum concentrations, 
(Glynn et al. 2012; Olsen et al. 2012; Schroter-Kermani et al. 2012). Higher ng/ml 
serum concentrations of PFOS and PFOA have occasionally been detected, then 
associated with high local exposures due to contaminated food and ground water 
(Emmett et al. 2006; Hovgard et al. 2009). Temporal trend studies have shown that 
PFOS, the current and for a long time dominant PFAS congener in human serum in 
western countries (Glynn et al. 2012; Haug et al. 2009; Kato et al. 2011), now shows 
a decreasing trend together with PFOA in western countries (Haug et al. 2009; Kato 
et al. 2011; Olsen et al. 2012; Schroter-Kermani et al. 2012) including Sweden 
(Glynn et al. 2012; Figure 13). This is likely due to the phase-out of PFOS-related 
production in 2002 by the major manufacturer (3M, 2011) and an ongoing phase-out 
of PFOA by some manufacturers (U.S. EPA, 2010). In contrast, serum concentrations 
of PFBS, perfluorohexane sulfonate (PFHxS), perfluorononanoic acid (PFNA), 
perfluorodecanoic acid (PFDA) and perfluoroundecanoic acid (PFUnDA) in 
individuals living in the Swedish city Uppsala have been shown to increase (Glynn et 
al. 2011). The increase in PFBS levels is likely due to its introduction as a 
replacement chemical for the six- and eight carbon homologues (Ehresman et al. 
 5 
 
2007). The increase in PFHxS serum levels, different to the trend observed in other 
western countries (Olsen et al. 2012; Schroter-Kermani et al. 2012), could be due to 
the recent detection of PFHxS in Uppsala’s municipal water (Glynn 2012).  
 
Occupationally exposed individuals are highly exposed as compared to the general 
population. Studies on workers in PFASs manufacturing facilities have shown levels 
in the low µg/ml serum range (Olsen et al. 2003), i.e. up to a thousand-fold higher 
than in the general population. In Sweden, where no production of PFASs occur, the 
most highly exposed are likely professional ski waxers (Nilsson et al. 2010). The 
probable reason is that PFCAs are constituents of certain gliding waxes (Freberg et al. 
2010) and a correlation between serum concentrations of PFCAs and the number of 
working years have been found, in contrast to serum concentrations of PFSAs where 
no such correlations have been found (Nilsson et al. 2010). 
 
1.2.7 Kinetics and tissue distribution 
1.2.7.1 Absorption 
Studies in rodents have shown high oral absorption of PFASs. In rats, bioavailability 
of nearly 100% have been shown for PFOS, PFOA and perfluorohexanoic acid 
(PFHxA) (Gannon et al. 2011, Gibson and Johnson 1979; Johnson et al. 1979) and 
high absorption rates have also been demonstrated for perfluorobutanoic acid (PFBA) 
and PFBS (Chang et al. 2008; Olsen et al. 2009). Absorption for other congeners can 
also be assumed to be high based on their similar physicochemical properties. 
Quantitative studies on other exposure routes, i.e. inhalation or dermal absorption, are 
lacking. However, toxicity studies on PFOS and PFOA using these exposure routes 
demonstrate absorption based on observed toxic effects (Kennedy et al. 2004; OECD 
2002). No human PFASs absorption data is available. 
 
1.2.7.2 Distribution 
PFASs tissue distribution data are limited. A few animal studies have until now 
investigated the tissue distribution of PFOS, PFOA and PFDA, showing that these 
PFASs are present at the highest levels in liver and serum, followed by kidneys and 
lungs (Hundley et al. 2006; Johnson et al. 1979; Kudo et al. 2006; Vanden Heuvel et 
al. 1991a, b). These findings have been confirmed in a human post-mortem study 
showing highest levels of PFOS in liver, lungs, kidneys and blood and highest levels 
of PFOA in lungs, kidneys, liver and blood (Maestri et al. 2006). However, detailed 
tissue distribution data have been essentially nonexistent for all PFASs, including 
different life-stages and doses, with the exception of one study using two doses of 
PFOA in rats, showing a larger proportion distributed to liver at the lower dose and a 
larger proportion distributed to serum and other tissues at the higher dose (Kudo et al. 
2006). The characteristic distribution of PFASs to liver and serum is, at least partly, 
due to their high affinity to proteins. A large number of PFASs have been shown to 
be highly bound to serum albumin (Bischel et al. 2011; Kerstner-Wood et al. 2004) 
and PFOS and PFOA have been shown to bind to the liver-fatty acid binding protein 
(L-FABP), a hepatic intracellular fatty-acid binding protein (Luebker et al. 2002). 
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A 1:1 ratio for human serum and plasma levels of a number of PFAAs have been 
shown (Ehresman et al. 2007) and levels in these matrices can thus be considered 
comparable. Also, a 2:1 ratio for serum to whole blood was shown, equal to the 
volume displacement by the red blood cells in serum. Thus whole blood levels of 
these PFAAs can be doubled to obtain their corresponding serum levels. This could 
be assumed also for other PFAAs based on their similar physicochemical properties. 
In contrast, the non-charged perfluorooctane sulfonamide (PFOSA) was shown to 
deviate from this ratio and distributes to a larger extent to whole blood than plasma 
(Kärrman et al. 2006).  
 
1.2.7.3 Metabolism 
No metabolism has been shown for PFSAs or PFCAs. Studies on PFOS, PFOA and 
perfluorodecane sulfonate (PFDS) in rats have shown that they are excreted without 
forming any metabolites or conjugates (OECD 2002; U.S. EPA 2005; Vanden Heuvel 
et al. 1991). Thus, PFSAs and PFCAs are believed to represent metabolically inert 
and stable end-stage products. However, certain precursor PFASs have in rodents 
been shown to transform, to various extents, into their perfluorinated sulfonate or 
carboxylate “backbone structures”, e.g. PFOSA and N-ethyl perfluorooctane 
sulfonamidoethanol (N-EtFOSE) into PFOS, and the polyfluorinated 8:2 FTOH into 
PFOA and PFNA (3M 2003; Henderson and Smith 2007; Seacat and Luebker 2000). 
 
1.2.7.4 Excretion 
One characteristic for PFASs is a marked difference in elimination kinetics depending 
on carbon chain length, species and sex (reviewed in Lau 2012a, Table 1). The major 
elimination route of PFASs is urinary excretion and to a smaller extent biliary and 
fecal excretion (Han et al. 2012). In general the rate of elimination from serum 1) 
increases with decreasing carbon chain length, 2) occurs more rapidly in rats > mice > 
non-human primates > humans, 3) is faster for carboxylates than for the 
corresponding sulfonates, and 4) show pronounced sex differences within certain 
species (e.g., faster elimination in female rodents). The reason for these differences in 
elimination is likely that PFASs are substrates to renal organic anion transporters 
(Han et al. 2012), regulating active renal reabsorption, and these transporters are 
differentially expressed between species and sex and have shown varying affinities 
for different PFASs carbon chain lengths (Han et al. 2012; Kudo et al. 2002; Weaver 
et al. 2010). 
 
In both humans and animals, PFASs are transferred to the fetus via the placenta and 
to the offspring via breast milk (reviewed in ATDSR 2009). Studies in humans have 
shown varying rates of placental and breast milk transfer between congeners, with 
levels in fetal serum ranging from 30% to 200% of that in maternal serum, but with 
most congeners showing a lower concentration in fetal serum (reviewed in Fromme et 
al. 2010; Gutzkow et al. 2012; Kim et al. 2011; Liu et al. 2011). Levels in breast milk 
have been shown to range from 1% to 12% of that in maternal serum (Kärrman et al. 




Table 1. Serum half-lives of PFAS congeners in different species (including humans). 
Congener Rat Mouse Monkey  Human References 
PFBS 0.6 - 4.0h (♀)  
2.1 - 4.5h (♂)  
NA 15h - 3.5d (♀) 
8.1h - 4d (♂)  
46d (♀) 
24d (♂)  
Chengelis et al. 2009; Olsen et al. 2009 
PFHxS 1d (♀) 
30d (♂)  
25 - 27d (♀) 
28 - 31d (♂)  
87d (♀) 
141d (♂) 
8.5y Olsen et al. 2007; Sundstrom et al. 2012a 
PFOS 62 - 71d (♀) 
38 - 41d (♂) 
30 - 38d (♀) 
36 - 43d (♂) 
110d (♀) 
132d (♂) 
5.4y  Chang et al. 2012; Olsen et al. 2007  
PFBA 1 - 2h (♀) 
6 - 9h (♂)  
3h (♀) 
5 - 16h (♂)   
1.7d (♂, ♀) 3.6d (♀) 
3.0d (♂) 
Chang et al. 2008 
PFHxA 0.4 - 1.2h (♀) 
1.0 - 2.4h (♂) 
N.A. 2.4h (♀) 
5.3h (♂) 
N.A. Chengelis et al. 2009; Gannon et al. 2011; Ohmori et al. 2003 
PFOA 2 - 4h (♀) 





3.8y Butenhoff et al. 2004; Kemper and Jepson 2003; reviewed in 
Lau et al. 2007; Ohmori et al. 2003; Olsen et al. 2007  
PFNA 1 - 2d (♀)  
30 - 31d (♂) 
26 - 68d(♀) 
34 - 69d (♂) 
NA NA Ohmori et al. 2003; Tatum-Gibbs et al. 2011 
PFDA 59d (♀)  
40d (♂) 
NA NA NA Ohmori et al. 2003 




1.2.8 Toxicity  
1.2.8.1 Hepatotoxicity 
Different PFASs show relatively similar toxicological profiles. Repeated-dose studies 
in rodents and monkeys point out the liver as a main target organ (Lau et al. 2007). The 
PFASs-induced hepatotoxicity is on a cellular level, with increasing dose, manifested 
as hepatocellular hypertrophy → hepatocellular vacuolation → hepatocellular 
pigmentation → hepatocellular necrosis (reviewed in ATSDR 2009). The 
hepatocellular hypertrophy (liver cell enlargement) occurs rapidly following PFASs 
exposure, aggravating little with time, and is reversible upon cessation of exposure. The 
hepatocellular vacuolation (formation of cytoplasmic vacuoles), and pigmentation 
(accumulation of lipofuscin, believed to represent lysosomal accumulation of poorly 
digested lipid (Haschek et al. 2002)), observed at higher doses (Butenhoff et al. 2012), 
have also shown to be reversible after end of exposure. At the highest dose levels 
hepatocellular necrosis (cell death) occurs. In addition, increased liver weight occur 
following PFASs exposure in rodents as well as non-human primates, and PFOS and 
PFOA have been shown to cause liver tumors in rodents likely via non-genotoxic 
mechanisms (reviewed in Lau et al. 2007).  
 
1.2.8.2 Reproductive and developmental toxicity 
A number of PFASs have shown reproductive and developmental toxic properties 
following in utero exposure. The toxicity is manifested as reduced fetal, perinatal (the 
time period shortly before and after birth) and/or neonatal (newborn) body weight and 
viability as well as reduced pup body-weight gain and litter loss in the dams (reviewed 
in Lau et al. 2007). The most adverse of these toxic effects is a dose-dependent marked 
increase in neonatal mortality that has been observed for PFOS, PFOA and PFNA 
(reviewed in Lau et al. 2004; Wolf et al. 2007, 2010). On the basis of labored 
breathing and cyanosis, the neonatal mortality is proposed to be due to disrupted 
pulmonary function, but the exact reason has not been clarified. For PFOS, 
morphological indications of delayed or impaired lung maturation have been shown  
(Grasty et al. 2003, 2005) and a direct interaction of PFOS with components of the 
pulmonary surfactant has also been suggested as an underlying mechanism (Abbott et 
al. 2009; Lehmler et al. 2006). Cross-fostering studies have revealed that the effects 
occurring after PFOS and PFOA exposure are due to gestational exposure (Luebker et 
al. 2005a; Wolf et al. 2007) and a critical window of exposure has been identified with 
administration as late as gestational day (GD) 19 being sufficient to induce this toxicity 
(Grasty et al. 2003). 
 
In addition, PFOS and PFOA have shown also other reproductive/developmental 
toxic effects in rodents following in utero exposure, such as developmental 
neurotoxicity (Johansson et al. 2008; Onishchenko et al. 2011; Viberg et al. 2013) 
delayed sexual maturation (Lau et al. 2004), impaired mammary gland development 
(White et al. 2007) and histopathological changes in the female reproductive tract 





1.2.8.3 Other types of toxicity 
In addition to hepatotoxicity and reproductive/developmental toxicity, other common 
toxic effects observed in rodents and primates following repeated PFASs exposure 
include decreased body weight, effects on lipid metabolism (decreased serum 
cholesterol and triglycerides) and thyroid hormone levels (decreased triiodothyronine 
(T3) and thyroxine (T4)), immunotoxicity (atrophy of thymus and spleen and reduced 
antigen response) (reviewed in Lau et al. 2007) and respiratory distress also in adult 
rodents (Cui et al. 2009). In addition, exposure of mice to a low dose of PFOA in 
utero has been shown to induce overweight and affect metabolic hormone levels in 
adult life (Hines et al. 2009).  
 
1.2.9 Mode of action 
The mode(s) of action for PFASs has not been clarified. PFASs show a structural 
analogy to endogenous fatty acids (reviewed in Lau 2012a) and are treated as fatty 
acids in the body, such as transport on albumin in blood (Bischel et al. 2011) and 
intracellular binding to fatty acid binding proteins (FABP) (Luebker et al. 2002). 
Also, as endogenous fatty acids, PFASs are ligands of the peroxisome-proliferator 
activated receptor alpha (PPAR-α) (Wolf et al. 2008), a nuclear receptor and regulator 
of lipid metabolism (Berger and Moller 2002). Compounds that bind PPAR-α induce 
proliferation of peroxisomes (“peroxisome proliferators”) leading to catabolism of 
fatty acids and cholesterol, particularly in the liver which is the main organ for lipid 
storage and mobilization (Lee et al. 2003). Peroxisome proliferators induce 
hepatocellular hypertrophy and increased liver weight by increasing the number and 
size of peroxisomes (Berger and Moller 2002). Peroxisome proliferators are also 
associated with liver tumors in rodents, however this effect is not considered relevant 
for humans since it is not observed in humans or non-human primates (Peters et al. 
2005). PFASs have shown increasing affinity for PPAR-α with increasing chain 
lengths in vitro and PFCAs were stronger activators of PPAR-α than PFSAs (Wolf et 
al. 2008). On the other hand, it has also been shown that increased liver weight and 
peroxisomal β-oxidation in rodents following PFASs exposure is not correlated to the 
length of the carbon chain, but to the hepatic concentration of the congener (Kudo 
and Kawashima 2003; Kudo et al. 2000, 2006). In humans the PPAR-α receptor is 
expressed to a lower extent than in rodents and appears to be less sensitive to the effects 
of PFASs (Albrecht et al. 2013; reviewed in Klaunig et al. 2003; Wolf et al. 2008, 
2012). Though PFASs bind PPAR-α and induce effects similar to peroxisome 
proliferators in rodents and non-human primates PFOS have been shown to do so 
without affecting markers for peroxisome proliferation, indicating that other 
mechanisms of action are involved (Lau et al. 2007). This is supported by findings in 
PPAR-α knockout mice showing hepatotoxicity following exposure to PFOA, but not 
following exposure to the prototypic PPAR-α-ligand WY 14,643, suggesting that 




Figure 2. HE-stained livers from wild-type SV/129 mice. Control wild-type mice (1a, 200x original mag). Wild-type 
mice (1b, 600x original mag) treated with 10 mg/kg PFOA had diffuse hepatocyte hypertrophy with numerous 
eosinophilic cytoplasmic granules that were morphologically consistent with peroxisome proliferation. There was 
also accumulation of small, clear cytoplasmic vacuoles. Wild-type mice (1c, 600x original mag) treated with Wyeth 
14,463 had similar hepatocyte alterations to the PFOA-treated mice. Reprinted from Wolf et al. (2008) with 






Regarding reproductive/developmental toxicity, studies in rodents have shown that 
the neonatal mortality following in utero exposure to PFOA and PFNA are PPAR-α-
dependent (Abbott et al. 2007; Wolf et al. 2008), but PPAR-α independent for PFOS 
(Abbott et al. 2009) indicating other mechanisms of action. Direct chemical 
interactions with pulmonary surfactant have been proposed (Abbott et al. 2009; 
Lehmler et al. 2006; Xie et al. 2007). Also, activation of other nuclear receptors by 
PFASs have been revealed, such as other PPARs (β and γ) as well as the pregnenolone 
X receptor (PXR) and the constitutive androstane receptor (CAR) (Bjork et al. 2011; 
Elcombe et al. 2010, 2012), adding more complexity into the mechanisms of action of 
PFASs. Human and mouse PXR and CAR have been shown to respond similarly with 
regard to hepatocellular hypertrophy and increased liver weight following exposure to 
e.g. phenobarbital and chlordane (Ross et al. 2010), and it cannot be excluded that the 
response could be similar also for PFASs. In addition, other modes of action of PFASs 
have been proposed, such as oxidative stress, effects on cell-signaling pathways, 
epigenetic changes, interference with cell communication and alterations in 
mitochondrial bioenergetics (reviewed in Lau 2012a, b).  
 
Though some effects by PFASs are mediated via PPAR-α, there are strong indications 
that other mechanisms are involved in e.g. hepatotoxicity and reproductive toxicity. 
Since the mechanism(s) of action of PFASs have not been clarified, and no evidence 
have been presented that would rule out these effects from occurring in humans, it is 
reasonable to consider these endpoints of human relevance.  
Figure 3. HE-stained livers from PPAR-α knockout mice. Control PPAR-α knockout mice (2a, 200x original mag) 
had scattered clear cytoplasmic vacuoles morphologically consistent with lipid accumulation. PPAR-α knockout mice 
treated with 10 mg/kg PFOA (2b, 400x original mag) had diffuse accumulation of clear, variably sized cytoplasmic 
vacuoles with fuzzy borders. PPAR-α knockout mice treated with Wyeth 14,463 (2c, 200x original mag) were not 
different from control mice. Reprinted from Wolf et al. (2008) with permission from SAGE Publications.  
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1.2.10 Epidemiological data 
Epidemiological studies on PFASs are available for general and highly exposed 
populations. Concerning effects of PFASs on the liver, studies have been performed 
in PFASs productions workers but with no associations being found between 
increasing levels of PFOA or PFOS/PFOA and changes in the measured biomarkers 
of hepatotoxicity (Costa et al. 2009; Olsen et al. 2003).  
 
Concerning reproductive toxicity, some studies have reported associations between 
PFASs exposure and reduced birth weight whereas others have not. In the general 
population, one study observed an association between increased serum levels of 
PFOA and PFOS in umbilical cord blood and decreased birth weight (Apelberg et al. 
2007). Two studies reported either a correlation between increased maternal plasma 
levels of PFOA, but not PFOS, and decreased birth weight, (Fei et al. 2007) or 
between increased maternal serum levels and decreased birth weight for PFOS but not 
for PFOA (Washino et al. 2009). Two other studies did not find any correlations 
between maternal serum levels of different PFASs and birth weight in the general 
population (Grice et al. 2007) or between serum levels of PFOS in production 
workers and pregnancy outcome (Monroy et al. 2008). In a population highly exposed 
to PFOA via contaminated drinking water, no clear associations were found between 
serum levels of PFOA and pregnancy outcomes or birth defects (Nolan et al. 2009, 
2010, Savitz et al. 2012a, b); though weak and/or inconsistent associations with early 
preterm birth, fetal growth restriction and pregnancy induced hypertension were seen 
(Savitz et al. 2012a, b). These conclusions by Nolan et al. and Sawitz et al. were also 
shared by an independent scientific panel (C8 Science Panel 2011a, b, c, d). 
 
Regarding other effects than hepatotoxicity and reproductive toxicity, some studies 
have found associations between increased serum levels of PFOA and serum levels of 
cholesterol and/or uric acid in PFASs production workers (Costa et al. 2009) and in a 
population highly exposed to PFOA via contaminated drinking water (Frisbee et al. 
2010) whereas others have not found any associations (Emmett et al. 2006) or 
considered the data insufficient for firm conclusions (Steenland et al. 2010). The 
indications of an association between increasing serum levels of PFOA and 
cholesterol points in the opposite direction to the decreased levels of serum 
cholesterol often observed in animal studies following PFASs exposure. Studies on 
immunotoxicity, metabolic effects or mammary gland development are limited. One 
study reported an association between increasing levels of PFASs and decreased 
antibody response following vaccination in children (Grandjean et al. 2012) whereas 
another study did not find any correlation between prenatal exposure to PFOS and 
PFOA and increased risk of severe infectious diseases in early childhood (Fei et al. 
2010). One study reported an association between increasing levels of PFOA during 
in utero exposure and overweight/obesity in females at 20 years of age in the general 
population whereas in another study in a population highly exposed to PFOA no clear 
associations were found between prenatal serum levels of PFOA and increased risk of 




1.2.11 Hazard/Risk assessment information  
Hazard and/or risk assessment information on PFASs is primarily available for the two 
most studied congeners PFOS and PFOA. These have been assessed by national and 
international authorities and organizations such as the European Chemicals Agency 
(ECHA 2011), the European Food Safety Authority (EFSA 2008), the Swedish 
Chemicals agency (KemI 2004), the United States Environmental Protection Agency 
(U.S. EPA 2005, 2009) and the Organization for Economic Co-operation and 
Development (OECD 2002) as well as by the industry (3M 2003). Though hazard/risk 
assessment information is lacking for the vast majority of other congeners, some 
attention in this regard have been given to other PFASs such as PFBS (NICNAS 2005; 
MDH 2011a), PFBA (MDH 2011b) and a large number of PFASs that were addressed 
in a recent cumulative risk assessment of PFASs (Borg and Håkansson 2012, preceding 
work to Paper IV in this thesis). 
 
1.2.12 Regulations 
In 2002, the largest producer of PFOS and PFOS-related compounds (all precursors 
that can be degraded to PFOS) discontinued its production of these substances 
(OECD 2005). Since then, other risk-reducing measures have also been taken within 
e.g. the European Union (EU) and the United Nations to reduce the use of PFOS. 
PFOS and PFOS-related compounds were prohibited from use in chemical products 
and articles within the EU in 2008 (EU 2006) and were in 2009 included in the 
Stockholm Convention on Persistent Organic Pollutants (UNEP 2009) as well as in 
the Convention on Long-Range Transboundary Air Pollution (CLRTAP) (UNECE 
2009) resulting in restrictions on their use. Although these measures led to a 
markedly decreased use of PFOS (KemI 2006), it is still produced elsewhere (UNEP 
2008), particularly in China where the production of PFOS increased substantially 
after 2002 (Xie et al. 2013). To replace PFOS, several manufacturers have moved 
towards other per- or highly fluorinated compounds, such as fluorotelomers and 
shorter alkyl chain sulfonates, such as PFBS, sharing similar technical properties as 
PFOS (KemI 2006, 2009).  
 
Regarding regulations of other PFASs than PFOS and PFOS-related compounds, 
PFUnDA, perfluorododecanoic acid (PFDoDA), perfluorotridecanoic acid (PFTrDA) 
and perfluorotetradecanoic acid (PFTeDA) have in the European Union’s chemicals 
legislation REACH (Registration, Evaluation, Approval and restriction of CHemicals) 
been classified as Substances of Very High Concern (SVHCs) based on their very 
persistent and very bioaccumulative (vPvB) properties (ECHA 2012a, b, c, d). In 
addition, PFOA and its ammonium salt, ammonium perfluorooctanoate (APFO) have 
been proposed as SVHS substances based on their toxicity to reproduction (BAuA 





1.3 WHOLE-BODY AUTORADIOGRAPHY 
Whole-body autoradiography (WBA) is a method to study the tissue distribution of a 
radiolabelled compound and/or its metabolites in an intact animal. Most commonly rats 
or mice are used, though also studies in e.g. guinea pigs, hamsters, rabbits, monkeys 
and non-mammalian species such as birds and fish have been performed (reviewed in 
Benard et al. 1985). The method, originally developed by Sven Ullberg in the 1950s 
(Ullberg 1954), has been used to investigate the tissue distribution of xenobiotics such 
as environmental contaminants, pesticides and metals (reviewed in Benard et al. 1985) 
though it is today mostly used by the pharmaceutical industry within preclinical drug 
development (Solon 2012).  
 
The common procedure for WBA (described in Larsson and Ullberg 1981) entails a 
single dosing of a radiolabelled compound, with the route of administration depending 
on the compound and purpose of the study, and sacrifice of the animals by euthanasia at 
various time-intervals followed by deep-freezing at -75 C in a carboxymethylcellulose 
(CMC) gel. Sections, commonly between 20-50µm thick, are then taken at different 
levels of the animal in a cryomacrotome and placed on x-ray film. After an appropriate 
exposure period, the section and film are separated and the compound and/or its 
metabolites (i.e. the radioactivity) will appear on the developed film (see example 
Figure 4). The section can then be stained or used unstained as reference for 
interpretation of the autoradiograms. The advantage of this technique is that it provides 
high resolution images of the qualitative distribution of the compound and/or its 
metabolites at the tissue level. To obtain quantitative data, this method can be 
combined with e.g. liquid scintillation counting.  
 
Being a qualitative method for 25 years, quantitative whole-body autoradiography 
(QWBA) was developed in the 1970s. In QWBA, the whole-body sections are placed 
on phosphor imaging plates producing digital images of the radiation. Together with a 
radioactive scale this allows for digital image analyses and quantitation of the 




Figure 4. Example of a whole-body autoradiogram showing an adult male mouse 48 h after administration of a single 
oral dose of 35S-labelled PFOS. The brighter areas correspond to higher levels of radioactivity. Bf = brown fat, Br = 
brain, Gm = gastric mucosa, Hb = heart blood, Hm = hears muscle, Ki = kidney, Li = liver, Lin = large intestine, Lu 
= lung, Mu = muscle, Pa = pancreas, Sg = salivary gland, Sin = small intestine, Sk = skin, Sp = spleen, St = Stomach. 
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1.4 HEALTH RISK ASSESSMENT OF CHEMICALS 
1.4.1 Introduction 
Health risk assessment of chemicals is the process to estimate the risk for a human 
(sub) population following exposure to a particular chemical compound, taking into 
account the inherent properties of the compound, the associated uncertainties as well 
as the characteristics of the specific target system. The process is often performed 
with the purpose to define “safe” exposure levels and provide guidance/limit values, 
such as Tolerable Daily Intake (TDI) for the particular compound. 
 
1.4.2 Principles of health risk assessment 
The risk assessment process of chemicals includes four steps: 1) hazard identification, 
2) hazard characterization (dose–response assessment), 3) exposure assessment, and 
4) risk characterization (IPCS/WHO 2004; U.S. EPA 2013; Figure 5). The hazard 
identification and hazard characterization are often together called hazard assessment.  
 
1.4.2.1 Hazard assessment 
The hazard assessment step involves hazard identification and hazard characterization 
(often referred to as dose-response assessment).  
 
The hazard identification identifies what adverse health effects that are or can be 
associated with exposure to the particular compound, employing toxicological, 
epidemiological, toxicokinetic and mode/mechanism of action data. In the subsequent 
hazard characterization, the “critical effect(s)” (the most sensitive adverse toxic 
effect(s) that is/are considered relevant for humans) are defined. Then, the dose-
response relationship of the critical effect(s) are evaluated in order to define a “no 
effect” level, e.g. a No-Observed-Adverse-Effect-Level (NOAEL), a Lowest-
Hazard Assessment 
Hazard identification 
• Identification of adverse toxic effects 
 
Hazard characterization  
• Identification of critical effect(s) 
• Dose-response assessment 
• Derivation of reference dose  
Exposure Assessment 
• Identification of exposed (sub)populations  
• Characterization of exposure  
‐ Route(s) of exposure 
‐ Exposure levels 
‐ Duration of exposure 
Risk characterization 
• Comparison of exposure level(s) with reference dose 
‐ Does the exposure(s) pose a risk or not? 
 




Observed-Adverse-Effect-Level (LOAEL) or a benchmark dose (BMD) that can be 
used as a “point of departure”. To the point of departure, assessment factors for 
uncertainties in extrapolation of animal data to humans, for variability in susceptibility 
in human populations and for extrapolation of e.g. short-term toxicological studies into 
chronic exposure, are applied in order to derive a reference dose, i.e. a “safe” exposure  
level (Figure 6).  
 
1.4.2.2 Exposure assessment 
The exposure assessment step evaluates if any (sub) population groups are exposed to 
the particular compound and, if so, how, i.e. what are the exposure levels, the routes of 
exposure and the frequency and duration of the exposure.  
 
1.4.2.3 Risk characterization 
In the risk characterization, the exposure levels derived in the exposure assessment are 
compared with the derived (“safe”) reference dose from the hazard assessment. If the 
exposure exceeds the reference dose, the (sub) population(s) of interest is considered at 
risk. It is, however, important to be aware of that the term “risk” represents that the 
margin of safety is too small from a regulatory perspective, and not an indication that 
adverse health effects have occurred. 
 
1.4.3 Cumulative risk assessment 
Health risk assessment of chemicals normally evaluates the effects of single 
compounds in isolation. However, compounds in a mixture may act together and 
induce a toxic effect that is larger than by the individual compounds themselves. Thus, 






























Figure 6. Schematic illustration of the derivation of a reference dose. To a “no effect” level of a critical effect, 
assessment factors are applied to derive a “safe” exposure level.  
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Faust 2012). During the last decade the area of mixture toxicology has developed and 
mixtures are being more commonly tested (Kortenkamp et al. 2009). However, due to 
the infinite number of possible chemical mixtures it is practically impossible to 
experimentally test for more than a very limited set of all chemical combinations 
(Backhaus et al. 2010). Thus, there is a need for reliable methods to assess the risk to 
combined exposure to multiple chemicals via all relevant routes and pathways, 
defined as cumulative risk assessment (WHO 2009).  
 
Numerous methods have been developed to predict the toxicity and risk of mixtures 
based on their chemical composition and knowledge about the toxicities of the 
mixture components (Kortenkamp et al. 2009). Most of these methods are based on 
the concepts of Concentration Addition (CA) and Independent Action (Backhaus et 
al. 2010). CA assumes that the individual components act via a similar mode of 
action, only differing in their relative potency to elicit a toxic effect (Backhaus et al. 
2010), whereas independent action assumes that the individual components act 
independently of each other (Backhaus et al. 2010). Both concepts assume that no 
interactions occur between the mixture components (SCHER 2011). CA, the most 
broadly used and often the default assumption of these two concepts (Kortenkamp et 
al. 2009) is generally defined by the formula:   
 
∑
   
    
 
    = 1 where Ci* are the concentrations of individual substances 1 to n that 
elicits a fractional effect x (e.g. 50% mortality) and ECxi denote the equivalent effect 
concentrations of the single substances (e.g. EC50i), i.e. those concentrations that 
alone would cause the same quantitative effect x as the mixture. In the CA formula a 
mixture component can be replaced totally or in part by an equal fraction of another 
component without changing the overall combined effect.  
 
From CA a number of cumulative risk assessment methods have been developed, 
including the Hazard Index (HI), Point of Departure Index (PODI), Relative Potency 
Factors (RPF) and Toxic Equivalency Factors (TEF) (reviewed in Kortenkamp et al. 
2009; reviewed in Sarigiannis and Hansen 2012): 
 
The Hazard Index (HI) is defined as the sum of the respective Hazard Quotients 
(HQs) for individual mixture components, calculated as the ratio between exposure 
(e.g. daily intake) and a reference dose (e.g. tolerable daily intake (TDI)):  
 
HIi = ∑   
 
    
; where HQi = 
         
               
. HI > 1 indicates a risk.    
 
The Hazard Index has been proposed as the preferred approach when extensive 
mechanistic information of the mixture components is not available (SCHER 2011). 
It does not predict the overall health effect of the mixture, but provide a measure of 
the total risk based on the contributions by the individual components. Thus, the 
Hazard Index can be used to identify the largest contributors to a risk (Sarigiannis and 





If this use of assessment factors is a problem, the Point of Departure Index (PODI) 
can be used instead. It represents the sum of the exposure of each compound divided 
by its respective point of departure, and therefore does not take into account 
uncertainties of the dataset. Instead it is compared to a default reference safety factor, 
often 100 (Sarigiannis and Hansen 2012). 
 
PODIi = ∑
         
                   
 
    
 
The relative potency factor (RPF) approach is an application for compounds that are 
assumed to be toxicologically similar (U.S. EPA. 2000). The concentrations of the 
mixture components are scaled up relative to the concentration of an index compound 
and then summed up. The total toxicity of the mixture is then assessed in terms of the 
toxicity of the equivalent concentration of the index compound: 
 
Cm = ∑          
 
    
 
The toxic equivalency factor (TEF) is a specific type of RPF that was first developed 
for dioxins, describing the total equivalent quantity (TEQ) of an index compound. It 
is based on assumptions of a similar mechanism of action and parallel dose-response 
curves. The total toxicity of the mixture is assessed in terms of the toxicity of an 
equivalent concentration of an index compound. The total equivalent quantity, TEQ, 
is estimated by summation of the concentrations of mixture components multiplied by 
the respective TEFs: 
 
TEQ = ∑    
 





2 THE PRESENT INVESTIGATION 
2.1 AIMS  
The overall aims of the work in this thesis were to 1) generate new experimental data 
on the distribution of PFASs that can improve human health risk assessments of this 
class of compounds by using the mouse as a model for humans; and 2) assess human 
health risks associated with the current exposure levels of PFASs in Sweden.  
 
More specifically, the project objectives in part one was to: 
 In detail study the tissue distribution of PFOS in perinatal C57Bl/6 mice following 
in utero exposure in order to 1) from a distributional perspective contribute to 
clarify the mode of action for the PFOS-induced neonatal mortality, 2) provide data 
on the distribution of PFOS in perinatal rodents for use in human health risk 
assessment, and 3) provide information about potential new target organs for PFOS 
in perinatal rodents (Paper I).  
 
 In detail study the tissue distribution of PFOS in adult male C57Bl/6 mice at a high 
dose commonly used in experimental studies and at a low dose of human relevance 
in order to 1) provide data on the distribution of PFOS in adult rodents for use in 
human health risk assessment, in particular with regard to improving extrapolation 
of high experimental doses to low doses of human relevance, 2) provide 
information about potential new target organs for PFOS in adult rodents, and 3) 
from a distributional perspective contribute to clarify the mode of action for general 
systemic toxicity of PFOS (Paper II).  
 
 In detail study the tissue distribution of the replacement chemical for PFOS, PFBS, 
in male adult C57Bl/6 mice in order to 1) provide data on the distribution of PFBS 
in adult rodents for use in risk assessment, 2) provide information about potential 
new target organs for PFBS in adult rodents, and 3) compare the tissue distribution 
of PFBS with that of PFOS (Paper III).  
 
More specifically, the project objectives in part two was to: 
 Perform a cumulative risk assessment of 17 PFASs that have been analyzed in the 
Swedish population with the purpose to 1) perform the 1
st
 cumulative risk 
assessment of PFASs, 2) provide risk assessment data that is lacking for the 
majority of the individual congeners, 3) provide a practical example on the use of a 






2.2 MATERIALS AND METHODS 
The sections below provide a summary of the materials and methods used in this thesis. 
Detailed descriptions of the techniques, materials and methods used in the individual 
studies can be found in the associated publications and manuscripts.  
 
2.2.1 Papers I-III, Tissue distribution studies on PFASs 
2.2.1.1 Experimental animals and housing 
In Papers I-III, C57Bl/6 mice were used as model species to investigate the perinatal 
and adult tissue distribution of PFOS as well as the adult tissue distribution of PFBS. 
The mouse is an extensively characterized experimental animal and the C57Bl/6 strain 
is a widely studied murine strain.  
 
All animals were housed in the animal facilities of the Wenner-Gren Institute, 
Stockholm University, in polycarbonate cages with heat-treated pine-shavings for 
bedding, with access to a standard pellet diet and tap water ad libitum and with a 12h 
light/12h dark cycle, relative humidity of 40 - 60% and temperature of 22 ± 2 C. The 
animals were allowed to acclimatize for at least 1 week prior to the experiments. 
 
2.2.1.2 Chemicals 
All solvents and other chemicals used in synthetic and analytical procedures in the 
experiments were of pro-analysis quality. The 
35
S-sulfuric acid used for the synthesis 
of 
35
S-perfluorooctane sulfonate and 
35
S-perfluorobutane sulfonate (section 2.1.1.3) had 
a radiochemical purity of 100%.  
 
2.2.1.3 35S-perfluorooctane sulfonate and 35S-perfluorobutane sulfonate syntheses 
The synthesis of 
35
S-perfluorooctane sulfonate and 
35
S-perfluorobutane sulfonate were 
performed as described in Sundström et al. (2012). The batch of 
35
S-PFOS used in 
Paper I and the high daily dose exposures in Paper II had a specific radioactivity of 
31.8 mCi/mmol, a chemical purity of 97% (the major impurity being PFOA) and a 
radiochemical purity of 97%. The batch of 
35
S-PFOS used for low daily dose 
exposure in Paper II, designed to obtain a higher specific radioactivity, had a specific 
radioactivity of 59 mCi/mmol, a 90% chemical purity (10% being mainly PFOA) and 
a radiochemical purity of 95%. The batch of 
35
S-PFBS in Paper III had a specific 
radioactivity of 29.6 mCi/mmol, a chemical purity of 95% and a radiochemical purity 




2.2.1.4 Preparation of diet (Paper II and III) 
For preparation of diet for the low daily dose exposure in Paper II, 
35
S-PFOS was 
diluted with double-distilled water, mixed with powdered RMI (E) chow to obtain a 
concentration of 0.156 µg 
35
S-PFOS/g food with a radioactivity of 0.018 µCi/g food. 
Based on an average food intake of 4 g/day and a body weight of 20 g this 
corresponds to an exposure of 0.031 mg 
35
S-PFOS/kg/day. For preparation of diet for 
the high daily dose exposure in Paper II, 
35
S-PFOS was supplemented with an 
appropriate amount of unlabeled PFOS and thereafter diluted with double-distilled 
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water to obtain a final concentration of 156 µg 
35
S-PFOS/PFOS/g food with a 
radioactivity of 0.81 µCi/g food. Based on an average food intake of 3 g per day (the 
mice consumed less as an effect of PFOS in the diet) and a body weight of 20 g this 
corresponds to an exposure of 23 mg/kg/day. For preparation of the diet for exposure 
in Paper III, 
35
S-PFBS was supplemented with unlabeled PFBS (95% purity), diluted 
in double-distilled water and mixed with powdered chow to obtain a final PFBS 
concentration of 95.3 μg 35S-PFBS/PFBS/g food, corresponding to 0.32 μmol PFBS/g 
with a specific radioactivity of 3.5 μCi/g. This was the same molar dietary 
concentration as the high daily dosing of PFOS in Paper II.  
 
2.2.1.5 Animal exposure and preparations for analyses (Paper I) 
Six female C57Bl/6 mice received a single dose of 
35
S-PFOS (0.8 µCi/g, 12.5 mg 
PFOS/kg bw) on GD16, five of these via oral gavage and the sixth by intravenous 
injection (to address possible differences in bioavailability between these two 
administration routes). The animals were thereafter monitored visually each day for 
possible signs of toxicity until the time of sacrifice by exposure to gaseous CO2 on 
GD18 (two dams), GD20 (one dam) or PND1 (three dams and pups) for whole-body 
autoradiography and liquid scintillation counting of tissues. After sacrifice, the 
animals were placed in aqueous carboxymethyl cellulose (CMC) frozen in a bath of 
hexane cooled with dry ice. 
 
2.2.1.6 Animal exposure and preparations for analyses (Paper II) 
Male C57BL/6 mice were divided randomly into 6 groups of 3 mice. Three groups of 
mice were allowed to consume the low daily dose diet containing 0.156 µg PFOS/g 
for 1, 3 or 5 days and the 3 other groups received the high daily dose diet containing 
156 µg PFOS/g for the same period of time. Body weights were measured at the 
beginning and end of each period and the food consumption was estimated by 
subtracting the weight of the remaining food from the weight of the food initially 
supplied to each mouse. At the end of the feeding period, the mice were bled under 
iso-flurane anesthesia and sacrificed by cervical dislocation for liquid scintillation 
counting of 
35
S-PFOS in tissues. Blood samples were collected in capillary collection 
tubes containing anticoagulant and organs and tissues (liver, lungs, kidneys, heart, 
spleen, stomach, small and large intestine, epididymal fat, testes, inguinal fat pads, a 
muscle sample from m. quadriceps femoris, bone samples consisting of the whole 
femur and tibia, skin samples taken from the back between the two scapula, brain, 
thymus, thyroid gland and pancreas) were dissected out and washed in cold PBS. The 
stomach and intestines were emptied of their contents and washed carefully again 
with cold PBS. All tissues were weighed and stored frozen at -20 C prior to liquid 
scintillation counting and determination of hemoglobin content. For whole body 
autoradiography, two male C57BL/6 mice received a single oral dose (0.8 µCi/g, 12.5 
mg PFOS/kg) via gavage and were sacrificed 48h later by exposure to gaseous CO2, 




2.2.1.7 Animal exposure and preparations for analyses (Paper III) 
Male C57BL/6 mice were divided randomly into 3 groups of 3 mice each for liquid 
scintillation counting of 
35
S-PFBS in tissues, 2 additional mice were used for whole-
body autoradiography and 3 untreated mice were used for determination of normal 
hemoglobin levels. For liquid scintillation counting, each group of mice was allowed 
to consume 95.3 μg PFBS/g food for 1, 3 or 5 days. For whole-body autoradiography 
following 5-day exposure, the dietary concentration was the same but with a level of 
radioactivity increased to 9 μCi/g food to enhance detection. With an average food 
intake of 3.7 g/day and a body weight of 22 g this exposure corresponded to a dose of 
16 mg PFBS/kg/day (53 μmol PFBS/kg/day). At the end of the feeding period, the 
mice were bled under iso-flurane anesthesia and sacrificed by cervical dislocation for 
liquid scintillation counting of 
35
S-PFBS in tissues or sacrificed for whole-body 
autoradiography in a CO2 atmosphere and immediately frozen at -20 °C on a flat 
surface before being placed in aqueous CMC and frozen in a bath of hexane cooled 
with dry ice. For the liquid scintillation counting blood samples were collected in 
capillary collection tubes containing anticoagulant and organs and tissues (liver, 
lungs, kidneys, heart, spleen, stomach, small/large intestine, epididymal fat, testes, 
inguinal fat pads, a muscle sample from m. quadriceps femoris, the whole femur and 
tibia bones, skin samples (taken from the back between the two scapula), brain, 
thymus, thyroid gland, pancreas and cartilage from the thoracic bone) were dissected 
out. The stomach and intestines were emptied of their contents and carefully cleaned 
by washing with cold PBS. All tissues were then weighed and stored frozen at -20 ºC 
prior to liquid scintillation counting and determination of hemoglobin content. 
 
2.2.1.8 Whole body autoradiography  
For the whole-body autoradiography in Papers I-III, series of sagittal whole-body 
sections (20- and 40-µm thick) were taken at 8–15 different levels, collected onto 
tape (Scotch 6890, 3M Ltd., St. Paul, MN, USA) and freeze-dried. The tape sections 
were then air-dried, opposed to X-ray film at -20 °C that were subsequently 
developed. In Paper I and II, samples of liver, lungs, kidneys, brain and blood from 
adult males, dams, pups and the remaining fetuses were dissected out of the remains 
in the CMC blocks for liquid scintillation counting. 
 
2.2.1.9 Histology 
In Papers I and II, certain whole-body sections were stained with hematoxylin and 
eosin for comparison to the associated autoradiogram. Also, in Paper II, certain 
whole-body sections were stained for calcified bone using Von Kossa’s staining 
Further, In Paper III, certain whole-body sections were stained for cartilage and 
calcified bone using a combination of a modified protocol for Safranin O/Fast Green 





2.2.1.10 Tissue scintillation counting and quantification of hemoglobin 
In Paper I, tissue samples from the remains of the dams, fetuses and pups utilized for 
whole-body autoradiography were weighed, processed using the Solvable kit and 
analyzed in a liquid scintillation counter. The Solvable solubilization reagent was not 
found to quench or affect the counting efficiency of 
35
S-PFOS. The process from 
chemical synthesis to completion of liquid scintillation results took up to 91 days and 
measured decays per minute (dpm) levels that were at least 6 times higher than 
background level. The radioactivity measured was subsequently converted into µg 
35
S-PFOS/g tissue (wet weight) using the original specific radioactivity of this 
compound and compensation for radioactive decay. 
 




S-PFBS, respectively, were 
similarly as in Paper I determined in a liquid scintillation counter. In Paper II, entire 
organs/tissues following low daily dosing were subjected to liquid scintillation 
counting and determination of hemoglobin content, except for skin, whole bone and 
liver, from which portions were taken. Following high daily dosing, portions of the 
tissues were used. In Paper III, entire organs/tissues were used for liquid scintillation 
counting and determination of hemoglobin content, with the exception of liver, 
kidneys, brain, skin, cartilage and bone, from which portions were taken. First, blood 
and soft tissue samples were weighed and solubilized in Solvable and then divided 
into two parts: one for scintillation counting and the other for determination of 
hemoglobin. The samples were bleached with hydrogen peroxide. In this manner 
hemoglobin and PFOS or PFBS could be determined in the same solubilized sample. 
For solubilization of whole bone, a mixture of perchloric acid and hydrogen peroxide 
was utilized which did not allow for determination of hemoglobin. Two solubilization 
reagents did not influence the efficiency of liquid scintillation counting. Correction 
for the decay of 
35
S was made in all cases. When only a portion of an organ/tissue 
was assayed, the total amount of PFOS or PFBS present in the organ/tissue was 
obtained by adjusting for the total weight. However, in the case of the skin, muscle, 
whole bone and blood, the total weights were not determined, and instead literature 
values for the relative contributions of these tissues to total body weight were utilized 
(16.5% for skin, 38.4% for muscle and 10.7% for whole bone, and 8% for blood).  
 
In Papers II and III, hemoglobin contents in tissues were quantified using a 
hemoglobin assay kit. In this assay, hemoglobin is converted into a colored end-
product by utilization of a detergent and the end-product is directly proportional to 
the hemoglobin concentration in the original sample. The resulting contents are 
expressed as mg hemoglobin per g tissue or blood. To correct the PFOS or PFBS 
concentrations in each tissue for PFOS or PFBS derived from the blood present in the 
same tissue, the radioactivity per mg hemoglobin in blood was calculated; this value 
was multiplied by the mg hemoglobin in the specific tissue; and the value obtained 





2.2.1.11 Statistical analyses 
In Paper I, the data set was found to be normally distributed and demonstrated equal 
variances. For statistical comparisons between all groups, one-way analysis of 
variance (ANOVA) was performed followed by Bonferroni’s Multiple Comparison 
Test for group-wise comparisons.  
 
In Paper II, the data sets was also normally distributed and with similar variance in 
all cases. One-way ANOVA was performed followed by an independent two-tailed t-
test. 
 
In Paper III, one-way ANOVA was performed followed by Tukey’s post-test for 
multiple comparisons. To test for statistically significant trends, one-way ANOVA 
followed by post-test for linear trends was performed. An unpaired two-tailed t-test 
was utilized to test for statistically significant differences between two mean group 
values alone.  
 
2.2.1.12 Ethical permits 
The in-life phase of the work in Papers I-III was carried out at Stockholm University 
and was ethically approved by Northern Stockholm Ethical Committee for Animal 
Research (approval numbers N405/08 and N/183-10). 
 
2.2.2 Paper IV, Cumulative risk assessment of PFASs  
2.2.2.1 Exposure assessment 
Biomonitoring data (blood/serum concentrations) of all PFAS congeners analyzed in 
the Swedish population from 2006 and onwards, collected from reports within the 
Swedish Health-Related Monitoring Programme, other national reports and scientific 
publications were used in the exposure assessment. External (oral/inhalation/dermal) 
exposures were not included. Two population groups were identified: individuals 
exposed indirectly via the environment (i.e. the general population) and 
occupationally exposed professional ski waxers. Based on the low number of 
individuals in the biomonitoring studies the highest PFASs concentrations in samples 
from selected key studies were used. Congeners present at concentrations under the 
limit of detection were included and treated as being < limit of detection. To enable 
comparisons between blood and serum/plasma concentrations, whole blood 
concentrations were converted into serum/plasma concentrations using the 1:2 whole 
blood:serum/plasma ratio (Ehresman et al. 2007).  
 
2.2.2.2 Hazard assessment 
The toxicological endpoints evaluated in the hazard assessment were hepatotoxicity 
(hepatocellular hypertrophy, hepatocellular vacuolation, increased liver weight and 
increased liver-to-body ratio) and reproductive toxicity (reduced fetal/perinatal 
/neonatal viability, reduced body weight/body weight gain and litter loss in the dams). 
Also, other endpoints if observed at a lower dose level than hepatotoxicity and 
reproductive toxicity were included. Points of departure were PFASs serum/plasma 
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concentrations at the respective NOAELs, LOAELs or BMDs. The toxicological data 
and key studies/critical effects were collected from already existing hazard- and/or 
risk assessments and supplemented with additional published relevant data from 
literature searches in PubMed, i.e., studies on hepatotoxicity or reproductive toxicity 
published after the hazard/risk assessment reports as well as studies showing other 
effects at lower concentrations than for hepatotoxicity and reproductive toxicity. For 
congeners where data for hepatotoxicity and reproductive toxicity and/or 
corresponding internal doses were lacking, read-across extrapolation to the closest 
most potent congener for the respective endpoint was performed. The read-across was 
performed on an equivalent molar basis. From the points of departure, reference doses 
were derived by the use of appropriate assessment factors (AFs) (Reference dose = 
point of departure/AFs) in accordance with REACH guidelines (ECHA, 2010). The 
following AFs were applied: 
 
 Exposure duration: An AF of 2 was used for extrapolations of subchronic-to-
chronic and subacute-to-chronic exposure for hepatotoxicity. This rather low AF 
is motivated by the rapid onset of hepatotoxicity and a limited aggravation with 
time. For other effects, AFs of 3 and 6 were applied for subchronic-to-chronic and 
subacute-to-chronic exposure, respectively. 
 PODs: An AF of 3 was used for extrapolations from LOAEL to NOAEL in 
studies where no NOAEL could be established.  
 Interspecies differences: An AF of 2.5 was applied for extrapolations of data from 
animals to humans with regard to toxicodynamic differences. No AF for 
toxicokinetic differences between animals and humans was used since internal 
doses were directly compared between the two. 
 Intraspecies differences: AFs 10 and 5 were applied for the general population 
and workers (that is considered a more homogenous and less sensitive group than 
the general population), respectively, for differences in sensitivity among humans.  
 Read-across extrapolations: An AF of 3 was used for extrapolations from shorter 
to longer congeners based on differences in potency. Shorter congeners are 
generally less potent than their longer homologues and thus no AFs were used for 
read-across extrapolations from longer to shorter congeners. 
 
2.2.2.3 Risk characterization 
Hazard Quotients (HQs) were derived for all individual congeners by comparing their 
respective reference doses (points of departure/AFs) with the exposure to evaluate 
whether the exposure level is tolerable or not: HQ = 
        
              
, where a ratio < 1 
indicates a tolerable exposure level and a ratio > 1 indicates a non-tolerable exposure 
level. In addition, a cumulative risk characterization was performed for all the 
congeners combined by the derivation of Hazard Indexes (U.S. EPA, 1989) for 
hepatotoxicity and reproductive toxicity: Hazard Index = HQs. Toxicological data 
for other endpoints were only available for a few individual PFAS congeners and it is 
unclear whether other PFASs exert these effects, thus a Hazard Index could not be 
derived for these endpoints.  
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Figure 7. Autoradiograms of 40-μm sections of pregnant mice on gestational days (GD) 18 and GD20, 48 h and 96 
h, respectively, after administration of a single oral dose of 35S-labelled PFOS (12.5 mg/kg). Brighter areas 
correspond to higher levels of radioactivity. 35S-PFOS was readily transferred to the fetuses which on GD18 (A) and 
GD20 (B) generally demonstrated tissue levels similar to or higher than in the blood of the dams. In the dams, the 
liver and the lungs contained the highest levels of 35S-PFOS, and in the fetuses the kidneys (not observable) and the 
lungs contained the highest levels on GD18 and GD20, respectively. Bl = blood, Bo = bone, Br = brain, Hm = heart 
muscle, In = intestines, Ki = kidney, Li = liver, Lu = lung, Pl = placenta, St = stomach. Reprinted from Borg et al. 
(2010) with permission from Elsevier. 
2.3 RESULTS AND DISCUSSION  
2.3.1 Tissue distribution studies 
2.3.1.1 Tissue distribution of PFOS in perinatal and adult mice 
In Papers I and II the tissue distribution of 
35
S-labelled PFOS was for the first time 
investigated in detail in perinatal and adult animals, using C57Bl/6 mice.   
 
In Paper I, 
35
S-PFOS was readily transferred to the fetuses after exposure on GD16. 
On GD18, 48h after exposure, 
35
S-PFOS was found at highest levels in kidneys 
followed by liver and lungs, all at higher concentrations than in the dam’s blood. In 
fetuses and pups on GD20 and PND1, a pronounced elevation of 
35
S-PFOS 
concentrations were observed in the lungs, being highest of the perinatal tissues (Figure 
7 and Figure 8). In perinatal brains, there were regional distributions of 
35
S-PFOS and 
the average levels were higher than in maternal brain and similar to that of the maternal 
blood. 
35
S-PFOS levels were in the dams highest in the liver and lungs followed by 
blood. Also, 
35























































Figure 8. Autoradiograms of 40-μm thick sections of mouse fetuses on GD18 and GD20 and 
of pups on PND1 following exposure of the pregnant dams to a single dose of 35S-labelled 
PFOS (12.5 mg/kg) orally or intravenously on GD16. The fetus on GD18 (A) originate from 
a intravenously exposed dam and the fetus on GD20 (B) and pup on PND1 (C) from an 
orally exposed dam, respectively. These autoradiograms were treated identically with respect 
to exposure time and image processing. The brighter areas correspond to higher local levels 
of radioactivity. On GD18 (A), the level of 35S-PFOS was lower in fetal lungs than in the 
liver and with a relatively homogenous distribution. On GD20 (B), local levels in the lungs 
were higher than in the liver and the lungs demonstrated a somewhat heterogeneous 
distribution. On PND1 (C), local levels in the lungs was further increased displaying a more 
heterogeneous distribution. Br = brain, Ki = kidney, Li = liver, Lu = lung, St = stomach. 
Reprinted from Borg et al. (2010) with permission from Elsevier. 
 27 
 
Paper I is the first study to demonstrate a selective localization of PFOS to perinatal 
lung tissue. The results are in line with toxicity data indicating that the lung is a target 
organ for the toxicity of PFOS in perinatal rodents (Grasty et al. 2003; Grasty et al. 
2005; Lau et al. 2003; Luebker et al. 2005; Yahia et al. 2008) and that PFOS-induced  
neonatal mortality, at least partly, is due to respiratory distress. The exact cause of the 
respiratory distress observed in rodents after in utero exposure to PFOS has not been 
clarified. It has been proposed that PFOS could interfere with late stages of lung 
maturation, based on histological findings suggestive of immaturity of the neonatal 
lungs (Grasty et al. 2003, 2005). An alternative and/or complementary hypothesis is 
that PFOS, which has been shown to have a high tendency to partition into lipid 
bilayers (Lehmler et al. 2006), directly interacts with components of the pulmonary 
surfactant (Abbott et al. 2009; Lehmler et al. 2006) resulting in elevated surface 
tension and atelectasis, i.e. incomplete expansion of the lung, causing respiratory 
failure. Atelectasis has been observed in neonatal mice following in utero exposure to 
PFOS (Yahia et al. 2008) and PFOS has been shown to interact with and disturb the 
function of components of the pulmonary surfactant in vitro (Gordon et al. 2007; 
Lehmler et al. 2006; Xie et al. 2007). Our findings that PFOS is present in high levels 
in perinatal lungs following late gestational exposure is consistent with the hypothesis 
that PFOS directly impairs pulmonary function, possibly by interacting with 
pulmonary surfactant in the alveoli. PFOS was found at low levels in the amniotic 
fluid and is likely one source of the PFOS present in the lungs. Further, the 
localization of PFOS to adult lungs is consistent with findings that PFOS causes 
pulmonary congestion also in adult rats (Cui et al. 2009).  
 
After the lungs the liver displayed on average the highest levels of 
35
S-PFOS in the 
perinatal mice, approximately 2.5-fold higher than in maternal blood, though 
significantly lower than in the maternal liver that showed the highest 
35
S-PFOS levels 
in the dams. These findings are similar to other studies (Chang et al. 2009; Lau et al. 
2003; Luebker et al. 2005b; Thibodeaux et al. 2003) and confirm that the liver is a main 
target organ for PFOS.  
 
35
S-PFOS was also present in the perinatal brain at a level close to that of the 
maternal blood and significantly higher than in the maternal brain. This high level in 
the perinatal brain is likely due to the incomplete development of the perinatal blood–
brain barrier (Chang et al. 2009) and support the conclusion that PFOS can affect the 
central nervous system and cause behavioral defects in both mice (Johansson et al. 
2008) and rats (Butenhoff et al. 2009). 
 
Finally, bone tissue was in Paper I discovered as a potential toxicological target tissue 
for PFOS in perinatal mice. It may be that this presence of PFOS in the developing 
bones could contribute to the delayed ossification and cleft palate that has been 






2.3.1.2 Tissue distribution of PFOS in adult mice at different doses  
In Paper II, the tissue distribution of 
35
S-PFOS after dietary short-term exposure was 
determined in detail in adult male C57Bl/6 mice at two different doses, one similar to 
the high doses commonly used in toxicological studies and one 750-fold lower dose 
similar to human exposure levels. Also, the contribution of PFOS to the respective 
tissues by blood was adjusted for. The results showed that PFOS was recovered in a 
dose-dependent manner in all 19 tissues examined. The highest concentrations were 
detected in liver, lungs, blood and kidneys (Figure 9a, b), in line with previous findings 
(Johnson et al. 1979). The distribution profiles were qualitatively similar between the 
low and the high dose, however with a higher tissue:blood ratio at the higher dose. This 
shows that the tissue distribution profile can be qualitatively extrapolated from a high 
dose used in experimental studies to a low environmentally relevant dose. The lower 
tissue:blood ratios at the lower dose, were similar to those found in a study on human 
post-mortem material (Maestri et al. 2006) 
 
The major body compartments for PFOS deposition in mice was calculated based on 
tissue concentrations multiplied by the weight of the organ/tissue. For larger tissues, 
skin, muscle, whole bone and blood, literature values for their weights were used. The 
result showed that after 5 days exposure to the low dose the major body compartments 
were the liver > (whole) bone > blood > skin > muscle. Correspondingly, the major 
body compartments at the high dose were the liver > skin > blood > (whole) bone > 
muscle.  
 
In this experiment, bone was discovered as a possible toxicological target tissue for 
PFOS in adult male mice. When analyzed as a whole bone, the levels were similar to 
blood; however the autoradiograms revealed that PFOS in whole bone likely was 
localized to the bone marrow (Figure 9c, d).  
 
One unexpected finding was that blood hemoglobin levels were markedly increased in 
the mice exposed to the high dose, up to 40%. The reason for this erythropoietic effect, 
which has not been observed in any other study, is not known but could possibly be 








Figure 9. (A) Whole body autoradiogram of a 40-μm section of a mouse 48 h after administration of a single oral 
dose of 35S-PFOS (12.5 mg/kg), and (B) the same section with hematoxylin/eosin staining. (C) Autoradiogram of a 
40-μm section of a mouse femur 48 h after administration of a single oral dose of 35S-PFOS (12.5 mg/kg) and (D) the 
same section with von Kossa's staining for calcified bone. In (A) and (C) the brighter areas correspond to higher 
levels of radioactivity and in (D) dark areas correspond to calcified bone. In (B) unstained areas correspond to fat (as 
caudal of kidney, surrounding the intestines and sub dermal), body cavities and freezing artifacts (cracks). Bl = 
blood, Bm = bone marrow, Bo = bone, Br = brain, Fa = fat, Hm = heart muscle, In = intestine, Ki = kidney, Li = 
liver, Lu = lung, Pa = pancreas, Sk = skin, Sp = spleen, and St = stomach. Von Kossa's staining revealed that the 35S-
PFOS was present only in the bone cavities, i.e. bone marrow, and not in the calcified bone. Reprinted (adapted) 














2.3.1.3 Pattern of tissue distribution of PFBS and comparison to PFOS 
In Paper III, the tissue distribution of PFBS, the replacement chemical for PFOS, was 
for the first time studied in detail. Adult male mice were used in the same manner and 
at the same molar concentration as the high dose of PFOS in Paper II. Similarly, the 
contribution of PFBS to tissues by the blood was adjusted for. The results revealed the 
presence of PFBS in all the 20 different tissues examined. The tissue levels increased 
from 1 to 3 days of exposure but appeared to level off thereafter. After 5 days of 
treatment the highest levels of PFBS were detected in liver, gastrointestinal tract, 
kidneys, cartilage, blood, whole bone, lungs and thyroid gland. In comparison to PFOS, 
the PFBS exposure resulted tissue levels in 5-40-fold lower than for the corresponding 
molar exposure to PFOS. This is most likely due to the rapid elimination of PFBS as 
compared to PFOS. Also, a slightly different tissue distribution pattern was shown, 
with lower organ concentrations for e.g. liver and lungs relative to the concentrations in 
the blood. 
 
The estimated major body compartments for PFBS were whole-bone, liver, skin, blood 
and muscle. This is similar as for PFOS in Paper II, but with the exception that PFBS 
was estimated to be localized more to whole bone than to the liver, as was the case for 
PFOS. Similarly, as for PFOS, the autoradiograms revealed that PFBS in whole bone 
was more localized to the bone marrow than to the calcified bone itself.  
 
In this experiment the autoradiograms also revealed a distinct localization of PFBS to 
cartilage in the adult male mice, a finding that has not been previously reported. In 
addition, the autoradiograms also showed relatively high levels of PFBS in male genital 
organs, with the exception of testes.  
 
Also, as for PFOS in Paper II, the hemoglobin levels were increased following PFBS 
exposure, though being less pronounced. As for PFOS this erythropoietic effect could 
be connected to the localization of PFBS to the bone marrow.  
 
2.3.2 Cumulative risk assessment of PFASs  
Paper IV is the first study to evaluate the risks of cumulative exposure to 17 PFASs 
analyzed in the blood of the Swedish population. The cumulative approach selected 
was the Hazard Index approach. The study was performed as a risk assessment, 
including the different parts: hazard assessment, exposure assessment and risk 
characterization. The exposure data was derived from Swedish biomonitoring data 
(blood/serum levels of PFASs) in two populations; the general population and 
occupationally exposed professional ski waxers. The evaluated toxicity data consisted 
of publicly available data for hepatotoxicity and reproductive/developmental toxicity as 
well as other more sensitive toxic effects than hepatotoxicity and 




2.3.2.1 Exposure assessment 
The exposure assessment showed that the different PFAS congeners generally were 
found at low ng/ml levels in the general population, though some were under the limit 
of detection (Table 2). However, PFOS was found at higher ng/ml levels in a small 
subpopulation consuming contaminated fish. In the occupationally exposed 
professional ski waxers the levels of some congeners were significantly higher than in 
the average population, i.e. PFNA and PFOA reaching high ng/ml and low μg/ml 
levels in serum, being approximately 125 and 200 times higher than in the general 
population (Table 2). Temporal trend studies in the general population showed that 
the levels of PFOS, PFDS, PFOSA and PFOA seem to decrease whereas the levels of 
PFBS, PFHxS, PFNA, PFDA and PFUnDA in serum seem to increase (Figure 10). 
 
Table 2. Summary of Swedish human serum/plasma biomonitoring data on perfluoroalkylated and 
polyfluoroalkylated substances (PFASs) from key studies in the general population and occupationally exposed 
professional ski vaxers Selected concentrations represent the highest concentrations at the latest time-point in a 
temporal study or from a sample in a snapshot study taken no later than 2006.  
Congener 





PFBS 0.10 N.A.b 
PFHxS 8.0 8.6 
PFOS  27.5/204a 54 
PFOSA < 0.040 N.A.b 
PFDS 0.025 N.A.b 
PFBA N.A. 2.2 
PFPeA N.A. 0.28 
PFHxA < 0.22b 24 
PFHpA < 0.24b 40 
PFOA 5.2 1070 
PFNA 2.6 326 
PFDA 0.70b 48 
PFUnDA 0.83 5.6 
PFDoDA < 0.1 N.Ab 
PFTrDA < 0.15 N.Ab 
PFTeDA < 0.25 N.Ab 
6:2 FTS < 3.6b N.Ab 
N.A. = Not analyzed 
a = Highly exposed subpopulation  
b = Due to lack of exposure data the same value as for the general population will be used in the risk characterization.  
 
 
2.3.2.2 Hazard assessment 
The result of the hazard assessment showed that the different PFASs were relatively 
similar with regard to their potency for hepatotoxicity and reproductive toxicity with 
points of departure ranging from 4 - 89 and 4 - > 60 μg/ml serum, respectively (Table 
3) However, toxicity data with internal doses were not available for all congeners, 
thus data for 12 of the 17 congeners had to be extrapolated. Some PFASs also showed 
effects at lower doses than hepatotoxicity and reproductive toxicity such as 
immunotoxicity and effects on mammary gland development that were observed at 
levels of human exposure. Epidemiological studies on PFASs did not provide any firm 





Figure 10. Temporal trends of PFAAs and FOSA in pooled blood serum samples from primiparous nursing women 
(N = 413), living in Sweden 1996–2010. Red dots are the geometric means for each year. The red line is the 
regression line obtained after linear regression analyses of log-normal PFAA levels between 1996 and 2010. The 
black horizontal line is the geometric mean concentration of the whole study period. Reprinted from Glynn et al. 





Table 3. Summary of points of departure for hepatotoxicity and reproductive toxicity. Doses represent NOAELs if 
not stated other. For congeners lacking data, read-across from the closest most conservative congener on a molar 
basis has been performed. Original congener-specific data is marked in bold. 
Congener 
Point of Departure  










a 300 > 45
a 
PFHxS  1.0 89 > 10.0 > 60 
PFOS  0.025 4.04 0.1 4.9 
PFOSA  0.024b 4.03b 0.1b 4.9b 
PFDS  0.029b 4.85b 0.1b 5.9b 
PFBA  6.0 14 175 4.4 
PFPeA  0.04c 4.5c 0.55c 10.0c 
PFHxA  20 5.4
c 100 11.9
c 
PFHpA  20 6.2
c 0.76c 13.8c 
PFOA  0.06 7.1 0.86
d 15.7d 
PFNA  0.83
e 28.5 0.83 8.9 
PFDA  1.2 31.6
f 3.0 9.9
f 
PFUnDA 1.01f 34.6f 1.01f 10.8f 
PFDoDA  0.02
c 37.7f 1.10f 11.8f 
PFTriDA  1.19f 40.8f 1.19f 12.7f 
PFTeDA  1.28f 43.9f 1.28f 13.7f 
6:2 FTS  0.020b 3.45b 0.085b 4.2b 
a = Read-across on a molar basis from PFHxS 
b = Read-across on a molar basis from PFOS 
c = Read-across on a molar basis from PFOA 
d = BMDL/BMCL 
e = LOAEL 
f = Read across on a molar basis from PFNA 
 
 
Table 4. Summary of points of departure for PFAS congeners and effects observed at a lower effect concentration 
than for hepatotoxicity and reproductive toxicity.  
Congener 
Point of Departure  
Effect 
External dose 
(mg/kg bw/day, µg/l ) 
Internal dose 
(µg/ml serum) 
PFBS   Hematology ( hemoglobin and hematocrit) 60 a N.A.b 
PFHxS  Hematology ( hemoglobin) 0.3 a,c 44 c 
PFOS Immunotoxicity ( IgM response) 0.000166 a 0.0178 
PFBA ↓ serum cholesterol 3.0 a N.A.b 
PFOA 
Mammary gland development 0.005c,d  0.021c 
↑ adult  body weight, serum leptin and insulin 0.01 a,c N.A.b 
6:2 FTSe Nephrotoxicity 15a N.A.b 
N.A. = Not available 
a = mg/kg bw/day 
b = will not be used in the risk characterization based on the lack of serum concentration 
c = LOAEL 
d = µg/l water 





2.3.2.3 Risk characterization and conclusions 
The outcome of the risk characterization did not indicate any risk for hepatotoxicity or 
reproductive toxicity associated with PFASs exposure in the general population, 
neither for congeners assessed individually nor in combination, based on the 
individual Hazard Quotients and the cumulative Hazard Indexes that were all < 1 
(Table 5). The subpopulation that had consumed PFOS-contaminated fish, however, 
showed Hazard Quotients of 1.3 and 1.0, respectively, indicating concern. Also, 
regarding the more sensitive toxicological endpoints, immunotoxicity and disrupted 
mammary gland development, a risk was identified based on exposure to PFOS and 
PFOA, respectively, showing high Hazard Quotients of 229 and 18, respectively (Table 
7).  
 
For the occupationally exposed professional ski waxers a risk was identified for 
hepatotoxicity by PFOA and by all PFASs in combination (Table 6). For reproductive 
toxicity, a risk was identified by all PFASs in combination (Table 6). Also, as for the 
general population, a risk was identified for immunotoxicity and disrupted mammary 
gland development by PFOS and PFOA, respectively, showing very high Hazard 
Quotients of 228 and 1884, respectively (Table 7).  
 
Overall, this first attempt of a cumulative risk assessment of PFASs showed that the 
Hazard Index approach is a suitable method to apply for this class of compounds. In 
addition to the above presented conclusions, the study also identified the following data 
gaps that, if filled, would improve future risk assessments:  
 
 Additional hepatotoxicity and reproductive toxicity data for other congeners with 
internal dose measurements to reduce the number of extrapolations. 
 Additional immunotoxicity data and data on effects on mammary gland 
development for other congeners. 
 More knowledge on the mode- and mechanism of action on PFASs in order to 



























PFBS  0.108 1 335 0.000081 0.03  √ > 2 400 < 0.000060 < 0.03  √ 
PFHxS 8.50 1 780 0.0048 1.8  √ > 2 400 < 0.0035 < 1.9  √ 
PFOS 27.5/(204)b 162 0.17/(1.3)b 64.0 (√) √ 196 0.14/(1.0) 76.2 (√) √ 
PFOSA  < 0.040 161 < 0.00025 < 0.09  √ 196 < 0.0002 < 0.11  √ 
PFDS  0.035 65 0.00054 0.2  √ 65 0.0004 0.24  √ 
PFHxA  < 0.22 108 0.0020 0.8  √ 628 0.00046 < 0.25  √ 
PFHpA  0.135 125 0.0011 0.4  √ 628 0.00024 0.13  √ 
PFOA 5.24 142 0.037 13.8  √ 628 0.0083 4.5  √ 
PFNA  2.6 190 0.014 5.1  √ 356 0.0073 4.0  √ 
PFDA  0.70 70 0.010 3.8  √ 119 0.0053 2.9  √ 
PFUnDA  0.83 77 0.011 4.1  √ 119 0.0058 3.3  √ 
PFDoDA  < 0.03 84 < 0.00036 < 0.1  √ 119 < 0.00019 < 0.10  √ 
PFTrDA < 0.15 91 < 0.0017 < 0.6  √ 119 < 0.00088 < 0.48  √ 
PFTeDA  < 0.04 97 < 0.00041 < 0.15  √ 119 < 0.00022 < 0.12  √ 
6:2 FTS < 1.82 138 < 0.013 < 5.0  √ 196 < 0.011 < 5.9  √ 
  Hazard Index (HI) 
0.25 - 0.27 
(1.3 - 1.4) 
 
(√) √ 




N.A. = Not available/not applicable 
a - RCR = Exposure/DNEL, ratio < 1 = risk is considered controlled, ratio of > 1 = risk is considered not controlled 





























PFBS 5.6 3 560 0.002 0.04  √ > 4 800 < 0.0016 < 0.09  √ 
PFHxS 8.6 3 560 0.002 0.04  √ > 4 800 < 0.0018 < 0.1  √ 
PFOS 54 323 0.17 3.1  √ 392 0.14 8.0  √ 
PFOSA  < 0.040 323 < 0.00012 < 0.002  √ 392 < 0.00010 < 0.006  √ 
PFDS  0.035 108 0.00027 0.005  √ 131 0.00022 0.013  √ 
PFBA 2.2 560 0.0039 0.07  √ 352 0.0063 0.36  √ 
PFPeA  0.28 284 0.0015 0.03  √ 1 256 0.00035 0.02  √ 
PFHxA 24 284 0.11 2.0  √ 1 256 0.025 1.5  √ 
PFHpA 40 284 0.16 2.9  √ 1 256 0.036 2.1  √ 
PFOA 1070 284 3.8 69.0 √  1 256 0.85 49.3  √ 
PFNA  326 380 0.86 15.7  √ 712 0.46 26.5  √ 
PFDA  48 127 0.34 6.3  √ 237 0.18 10.6  √ 
PFUnDA  5.6 127 0.036 0.67  √ 237 0.019 1.1  √ 
PFDoDA < 0.03 127 < 0.00018 < 0.003  √ 237 < 0.000096 < 0.006  √ 
PFTrDA < 0.15 127 < 0.00082 < 0.015  √ 237 < 0.00044 < 0.03  √ 
PFTeDA  < 0.04 127 < 0.00021 < 0.004  √ 237 < 0.00011 < 0.006  √ 
6:2 FTS < 1.82 323 < 0.0066 < 0.12  √ 392 < 0.0054 < 0.32  √ 
  Hazard Index (HI) 5.5  √   1.7  √  






 Table 7. Individual Hazard Quotients (HQs) for other endpoints in individuals exposed indirectly via the environment and in occupationally exposed individuals. 
Congener Effect 














Yes No Yes No 
PFHxS Hematology 8.6 98 0.08  √ 8.6 196 0.04  √ 
PFOS Immunotoxicity  27.5 0.12 229 √  54 0.24 228 √  
PFOA 
Mammary gland  
development 








In summary, the results generated in Papers I-IV showed that:  
 
 PFOS was readily transferred to mouse fetuses after exposure of pregnant dams 
generating tissue levels that were similar to or higher than the levels in maternal 
blood. The distribution of PFOS to perinatal and adult lungs was substantial; 
being highest of all tissues analyzed in fetuses and pups on GD20 and PND1. 
These findings may, at least partly, explain the respiratory distress seen in 
neonatal and adult rodents following exposure to PFOS.  
 
 PFOS was recovered in all 19 examined tissues in adult male mice after short-term 
dietary exposure showing a similar tissue distribution profile between the high and 
the low dose but with a higher proportion of PFOS distributed to tissues as 
compared to blood at the higher dose. The highest PFOS concentrations were 
found in liver, lungs, blood, kidneys and whole bone and the major body 
compartments were liver, bone, blood, skin and muscle. Blood hemoglobin levels 
were markedly increased at the high dose which could be connected to the finding 
of significant localization of PFOS to bone marrow.  
 
 PFBS was recovered in all 20 examined tissues in adult male mice after short-term 
dietary exposure at the same molar concentration as the high dose of PFOS in Paper 
II. The distribution and compartment profiles were similar to those of PFOS but 
PFBS displayed significantly lower tissue concentrations and tissue:blood ratios 
than PFOS. An erythropoietic effect was seen also for PFBS, though less marked 
than for PFOS, and a pronounced distribution to cartilage was observed 
 
 The cumulative risk assessment of 17 PFASs analyzed in the Swedish population 
and in professional ski waxers showed that high local exposures and occupational 
exposure may be of concern for hepatotoxicity or reproductive/developmental 
toxicity but indicated no risk for the general population. Concern for 
immunotoxicity and altered mammary gland development was also identified for 
both the general population and the occupationally exposed. A need of additional 
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4 SVENSK SAMMANFATTNING  
I vårt moderna samhälle exponeras människor för en mängd olika kemikalier dagligen. 
Beroende på kemikaliernas inneboende egenskaper kan vissa av dessa ansamlas i 
miljön, även i områden långt från där de har tillverkats eller använts. Ett ökande antal 
studier pekar på att exponering för låga halter av vissa kemikalier kan ge upphov till ett 
brett spektrum av negativa hälsoeffekter såsom neurologiska och metabola sjukdomar, 
försämrat immunförsvar, försämrad reproduktionsförmåga och cancer.  
 
Perfluorerade och polyfluorerade ämnen (PFAS) utgör en stor grupp av mer än 800 
industriellt framställda högfluorerade kemikalier. De har på grund av sina ytaktiva 
egenskaper använts sedan 1950-talet för bland annat impregnering av material som 
papper och textiler, i rengöringsmedel och vaxer (inklusive skidvallor), i 





. I slutet av 1990-talet och början av 2000-talet upptäcktes att PFAS förekom i ett 
stort antal prover från vilda djur över hela världen och i prover från blodbanker i USA. 
Även om man tidigare vetat att det funnit fluor i människors blod så har det förrän vid 
denna tidpunkt funnits metoder för att analysera PFAS. Sedan dessa upptäckter gjordes 
har ett stort antal studier visat på förekomsten av PFAS i människor, djur och miljön 
över hela världen. Detta har lett till att PFAS har blivit klassade som extremt 
svårnedbrytbara miljöföroreningar och gett upphov till oro på grund av deras 
omfattande globala spridning. I den svenska befolkningen har hittills 17 stycken PFAS 
analyserats i blodprover. I djurstudier har PFAS visats ge upphov till en rad toxiska 
effekter varav effekter på levern och fosterutvecklingen är vanligt förekommande, men 
även påverkan på blodfetter och hormoner, kroppsvikt, immunförsvar och andning har 
setts. Detaljerad information om hur PFAS fördelas i kroppen är väldigt begränsad och 
kunskap om fördelningen i kroppen kan öka förståelsen om hur deras toxicitet uppstår. 
Hälsoriskbedömningsinformation har också saknats för de flesta PFAS förutom de mest 
studerade, perfluoroktansulfonat (PFOS) och perfluoroktanoat (PFOA).   
 
Syftet med mina studier har varit att 1) ta fram detaljerade data på distributionen av 
PFOS till olika organ och vävnader i perinatala (tiden före, vid och efter födseln) och 
vuxna möss samt för den kemikalie som numera används istället för PFOS -
perfluorbutansulfonat (PFBS) i vuxna möss, och 2) bedöma potentiella risker för 
människors hälsa kopplad till exponeringen för de 17 PFAS som analyserats i blodet på 
den svenska befolkningen, var för sig och alla tillsammans.  
 
Resultaten av mina studier visade att PFOS snabbt överfördes till musfoster efter 
dosering av moderdjuren. Deras vävnadsnivåer av PFOS var lika höga eller högre än 
nivåerna i moderdjurets blod. PFOS ansamlades markant i de perinatala lungorna där 
de förekom i högst halter av alla vävnader på dräktighetsdag 20 (dagen före födseln) 
och efter födseln. PFOS ansamlades även i hög grad i moderdjurens lungor. 
Sammantaget kan dessa resultat hjälpa till att förklara de effekter på andningen som 
tidigare setts i nyfödda och vuxna djur efter exponering för PFOS. En tänkbar 
verkningsmekanism är att PFOS, när det hamnar i lungorna, stör funktionen av den så 
 1
Med risk avses inte att det idag nödvändigtvis finns hälsoproblem på grund av kemikalien men visar 
på att marginalen mellan nuvarande exponeringsnivåer och toxiska effektnivåer är otillräcklig. En 
ytterligare förfining av riskbedömningen och/eller förebyggande åtgärder för att reducera exponeringen 
kan vara nödvändigt. 
 
 
kallade surfaktanten. Denna fungerar som ett ytspänningsnedsättande ytskikt i lungorna 
och möjliggör en normal andning.  
 
Vidare kunde PFOS mätas i alla 19 undersökta organ/vävnader i vuxna möss som 
exponerats under kort tid för PFOS via maten antingen för en låg dos, liknande den 
som människor utsätts för, eller en högre dos liknande den som ofta används i 
djurstudier. Distributionen såg likadan ut för de båda doserna men med skillnaden att 
mer PFOS fördelades till vävnaderna istället för i blodet vid den högre dosen. Detta 
visar att man kan överföra distributionsdata från höga doser av PFOS till låga doser. De 
högsta koncentrationerna av PFOS fanns i lever, lungor, njurar, ben (inklusive 
benmärg) och de största totala mängderna av PFOS återfanns i lever, ben (inklusive 
benmärg), blod, skinn och muskler. En vävnad som för första gången upptäcktes som 
”målvävnad” för PFOS var benmärg. Detta kan möjligen förklara de höga halterna av 
PFOS som återfanns när man mätte på hela skelettbenet. Ett annat anmärkningsvärt 
resultat var att hemoglobinnivåerna var tydligt förhöjda i högdosgruppen vilket kan 
indikera att PFOS utövar en hematopoetisk (blodcellsbildande) effekt i benmärgen.   
 
I ett ytterligare försök där PFBS gavs till vuxna möss i maten, på samma sätt och i 
samma dos som den högre dosen i det tidigare PFOS-försöket, kunde PFBS mätas i alla 
20 undersökta organ/vävnader. Distributionsprofilen var lik den för PFOS, men med 
skillnaden att nivåerna var 5-40 gånger lägre och att mindre PFBS återfanns i vävnader 
jämfört med i blodet. Höga halter av PFBS kunde också uppmätas i brosk. Även här 
kunde en hematopoetisk effekt ses, men i lägre grad än för PFOS.  
 
I det sista delarbetet gjordes en hälsoriskbedömning av exponeringen för de 17 PFAS 
som mätts i blodet hos den svenska befolkningen samt för högexponerade 
yrkesverksamma skidvallare. I studien undersöktes dels riskerna med varje PFAS-ämne 
individuellt (som oftast görs i en riskbedömning) samt för alla PFAS tillsammans vilket 
är första gången det görs för denna grupp av ämnen. Resultaten visade inte på någon 
risk
1
 för effekter på levern eller på utvecklingstoxiska effekter i den allmänna 
befolkningen associerade med PFAS, varken individuellt eller i kombination. Däremot 
så kunde en risk förknippas med lokalt höga exponeringar, t ex hos personer som ätit 
kontaminerad fisk. För de yrkesexponerade skidvallarna kunde en risk för dessa 
effekter associeras med exponering för enskilda PFAS-ämnen och/eller alla PFAS 
tillsammans. För både allmänbefolkningen och den yrkesexponerade gruppen kunde en 
risk för effekter på immunsystemet och utvecklingen av bröstkörtlar påvisas. Ett behov 
av ytterligare toxikologiska data för alla toxikologiska effekter som ingått i 
bedömningen identifierades också.  
 
Sammantaget har arbetet i denna avhandling genererat nya distributionsdata som kan 
användas för riskbedömning av PFAS. Den har också bedömt riskerna associerade med 
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